Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Practice Guidelines
    • Medicine Guidelines
    • GOI Antibiotic...

    GOI Antibiotic Guideline For Treatment of Muti-Drug Resistant Bacterial Pathogens

    Written by supriya kashyap kashyap Published On 2017-03-13T09:57:33+05:30  |  Updated On 13 March 2017 9:57 AM IST
    GOI Antibiotic Guideline For Treatment of Muti-Drug Resistant Bacterial Pathogens
    In 2016 National Centre For Disease Control, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India came out with National Treatment Guidelines for Antimicrobial Use in Infectious Diseases.

    Methicillin- Resistant S. aureus (MRSA)

    1. These organisms are considered resistant to all penicillins, cephalosporins and macrolides.

    2. Though MRSAstrains may be reported as susceptible to Fluoroquinolones, aminogycogides, chloramphenicol and doxycycline in-vitro, these drugs are NOT to be used alone or as initial treatment for serious MRSA infections.

    3. Rifampicin use should be avoided in diseases other than Mycobacterial diseases.

    4. The drug of choice for treatment of infections due to MRSA is the glycopeptides i.e Vancomycin and Teicoplanin.

    5. Linezolid can be used to treat skin and soft tissue infections caused by MRSA.

    6. Mupirocin local application (intranasally bid x 5 days) for eradicating nasal carriage.

    7. Daptomycin: Daptomycin is an intravenous antibiotic approved to be used for the treatment of complicated skin infections and Staphylococcus aureus bacteraemia. Daptomycin should NOT be used for treatment of pneumonia due to its inactivation by surfactant.


    Vancomycin Resistant Enterococcus (VRE)

    Enterococci are a therapeutic challenge because of their intrinsic resistance to many antibiotics. The acquisition of resistance to vancomycin by enterococci has seriously affected the treatment and infection control of these organisms. The treatment for VRE should be based on infection severity and in-vitro susceptibility of the strain to other antibiotics.

    • Linezolid: Linezolid is the only drug specifically approved for the treatment of VRE-blood stream infections. Linezolid may be particularly useful in patients who require oral or outpatient therapy (when intravenous therapy is undesirable), who are intolerant to glycopeptides, or who have impaired renal function. Linezolid is a bacteriostatic agent; furthermore, linezolid toxicity when administered for prolonged courses may limit its use in VRE endocarditis.

    • Ampicillin: Isolates that remain relatively susceptible to penicillin or ampicillin may be treated with high doses of these agents.

    • Daptomycin: Not approved for treatment of VRE infection. Not approved for treatment of endocarditis. Limited clinical information for VRE, but bactericidal activity makes consideration of this agent as sole therapy in serious infections. However, emergence of resistance during therapy has been reported.

    • Doxycycline: Not a first line therapy. For susceptible isolates, not for bacteremia or endocarditis. It should not be used as monotherapy.

    • Nitrofurantoin:Uncomplicated UTIs have been treated successfully with nitrofurantoin.

    • Fosfomycin: For urinary tract infections (cystitis) with isolates susceptible to fosfomycin.

    • Chloramphenicol: For chloramphenicol-susceptible isolates of E faecium and E. faecalis. Not a first-line therapy and it should not be used as monotherapy.

    • Gentamicin or streptomycin: To be used in combination with ampicillin for the treatment of enterococcal endocarditis caused by organisms susceptible in vitro to either agent; streptomycin is used when gentamicin cannot be used because of resistance.

    • Tigecycline: Tigecycline has in vitro activity against a broad spectrum of Gram-positive and -negative bacteria, anaerobes as well as multidrug-resistant pathogens such as MRSA and VRE. However, there is not much clinical dataregarding its use for treatment of VRE infections.


    Extended Spectrum Βeta-Lactamases (ESBL) Producing Enterobacteriaceae.

    1. ESBLs are plasmid mediated β-lactamases that confer resistance to broad spectrum β- lactum antibiotics including third and fourth generation cepahlosporins, azetronam, and extended spectrum penicillins. These plasmids often encode mutations which confere resistance to other broad spectrum agents including aminoglycosides, co-trimoxazole and fluoroquinolones, resulting in organism resistant to most broad spectrum antibiotics.

    2. A major problem with ESBLs is their capacity to cause therapeutic failure with cephalosporins and azetreonam when host organism appears to be susceptible to these agents in laboratory tests. Hence, CLSI recommends that laboratories should report ESBL producing isolates as resistant to all penicillins, cephalosporins (including cefepime and cefpirome), and azetreonam irrespective of in-vitro test results.

    3. The emergence of ESBL producing enterobacteriaceae is related to indiscriminate use of third generation cephalosporins.

    4. The carbapenems (Ertapenem, Meropenem and Imipenem) are currently considered the drug of choice for serious infections caused by these pathogens. Piperacillin–Tazobactam and Cefoperazone- Sulbactam may be considered options in mild infections and when ESBL producers are demonstrably susceptible in -vitro.


    Carbapenem- Resistant Enterobacteriaceae (CRE)

    a) Mechanism of resistance :

    1. Combinations of ESBL or AmpC and porin loss: Porin loss is often unstable and may impose afitness cost, meaning that these strains rarely spread. Ertapenem is particularly affected.

    2. Acquired carbapenemases


    b) Treatment :

    1. Most carbapenemase producers are extremely drug resistant: being resistant to β-lactam antibiotics, aminogycosides, and β-lactam–βlactam inhibitor combinations.

    2. Polymyxins, tigecycline & fosfomycin are the agents with most frequent in vitro activity, but all have limitations. Dosage will vary with the patient and infection site, but should be on the principle of ‘highest safe’ rather than ‘minimum potentially effective; durations should be as standard for the infection type.

    3. Colistin - Case reports of successful use in a range of infections due to carbapenemase producers.

    4. Tigecycline:Active in-vitro vs. most carbapenem-resistant E. coli. Licensed for complicated skin and soft-tissue Infections and complicated intraabdominal infections. Case reports of success in various infections with carbapenemase producers. Low blood concentrations; off-label use should be cautious for blood stream infections, unsuitable in urinary infections as only 22% excreted in urine. Excess deaths in some trials, especially ventilator associated pneumonia (not a licensed indication).

    5. Others: a few isolates are susceptible to other antibiotics including e.g. chloramphenicol, ciprofloxacin and cotrimoxazole. Most producers, however, are resistant to these drugs.


    Recommended measures to control spread of Multi-drug resistant organisms (MDRO) :

    1. Improved laboratory detection and reporting of MDRO.

    2. Enhanced infection surveillance and control in ICUs.

    3. Prevent spread by barrier precautions : Gowns and gloves.

    4. Hand Washing.

    5. Restricted use of 3rd generation cephalosporins.


    Directorate General of health servicesGovernment of IndiaguidelinesInfectious diseasesMinistry of Health & Family WelfareNational Centre For Diseasetreatment guidelinesTreatment of Muti-Drug Resistant Bacterial Pathogens

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok